MENU
+Compare
MLYS
Stock ticker: NASDAQ
AS OF
Apr 3 closing price
Price
$13.53
Change
-$0.47 (-3.36%)
Capitalization
850.29M

MLYS Mineralys Therapeutics Forecast, Technical & Fundamental Analysis

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more

MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for MLYS with price predictions
Apr 03, 2025

MLYS in downward trend: price may drop because broke its higher Bollinger Band on March 10, 2025

MLYS broke above its upper Bollinger Band on March 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 14 similar instances where the stock broke above the upper band. In of the 14 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for MLYS moved out of overbought territory on March 26, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator moved out of overbought territory. In of the 11 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on April 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In of 33 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MLYS turned negative on March 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

MLYS moved above its 50-day moving average on March 06, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MLYS crossed bullishly above the 50-day moving average on March 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MLYS advanced for three days, in of 108 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 63 cases where MLYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MLYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.446) is normal, around the industry mean (13.581). P/E Ratio (0.000) is within average values for comparable stocks, (64.662). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.879). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (248.206).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MLYS is expected to report earnings to rise 10.20% to -108 cents per share on May 19

Mineralys Therapeutics MLYS Stock Earnings Reports
Q1'25
Est.
$-1.08
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.42
Q2'24
Missed
by $0.11
Q1'24
Beat
by $0.02
The last earnings report on February 12 showed earnings per share of -98 cents, missing the estimate of -70 cents. With 1.11M shares outstanding, the current market capitalization sits at 850.29M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
150 North Radnor Chester Road
Phone
+1 888 378-6240
Employees
28
Web
https://mineralystx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSNCX14.43N/A
N/A
Touchstone Sands Capital Select Growth C
ANDNX15.65N/A
N/A
AQR International Defensive Style N
MIOPX28.41N/A
N/A
Morgan Stanley Inst International Opp A
PGJQX16.87N/A
N/A
PGIM Jennison Global Infrastructure R6
HLIZX25.98N/A
N/A
Harding Loevner International Eq Instl Z

MLYS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with PTGX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
-3.29%
PTGX - MLYS
47%
Loosely correlated
-3.53%
CKPT - MLYS
42%
Loosely correlated
+0.25%
ABOS - MLYS
34%
Loosely correlated
-8.65%
VCYT - MLYS
33%
Loosely correlated
-5.51%
CELC - MLYS
32%
Poorly correlated
-5.24%
More